Number and types of drug discontinuations among new antifibrotic users
| Nintedanib | Pirfenidone | Total | P value | |
| Discontinuation, n (%) | 55 (64.0%) | 80 (54.4%) | 135 (58.1%) | 0.016* |
| Cause of discontinuation | ||||
| Adverse events, n (%) | 36 (42.4%) | 34 (23.1%) | 70 (30.2%) | 0.012* |
| Lung transplantation, n (%) | 4 (4.7%) | 5 (3.4%) | 9 (3.9%) | 0.346* |
| Death | 15 (17.6%) | 41 (27.8%) | 56 (14.2%) | 0.834* |
| Type of discontinuation | ||||
| Dose reduction, n (%) | 31 (36.5%) | 35 (23.8%) | 66 (28.4%) | 0.039* |
| Drug change, n (%) | 31 (36.5%) | 23 (15.6%) | 54 (23.3%) | <0.001* |
| Temporary discontinuation, n (%) | 13 (15.3%) | 18 (12.2%) | 31 (13.4%) | 0.511* |
| Withdrawal, n (%) | 31 (36.5%) | 29 (19.7%) | 60 (25.9%) | 0.005* |
*Pearson’s χ2 test.